Odyssey Health, INC. (ODYY) — SEC Filings

Q: What are the key financial highlights for Odyssey Health, INC.?

Key financial highlights for Odyssey Health, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Odyssey Health, INC.?

Key executives at Odyssey Health, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Odyssey Health, INC. stock?

Risk factors for Odyssey Health, INC. (ODYY) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Odyssey Health, INC.?

Forward-looking statements and predictions from Odyssey Health, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Odyssey Health, INC.. Recent 8-K filing on Apr 24, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Odyssey Health, INC. on SEC EDGAR

Overview

Odyssey Health, INC. (ODYY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 19, 2025: Odyssey Health, Inc. (ODYY) filed an S-1 on December 19, 2025, to register 18,000,000 shares of common stock for resale by Mast Hill Fund, L.P. These shares will be issued upon the conversion of a $2,262,000 Maintenance Agreement Convertible Promissory Note, a $500,000 Purchase Agreement Note, and t

Sentiment Summary

Across 28 filings, the sentiment breakdown is: 4 bearish, 22 neutral, 2 mixed. The dominant filing sentiment for Odyssey Health, INC. is neutral.

Filing Type Overview

Odyssey Health, INC. (ODYY) has filed 16 8-K, 2 S-1, 6 10-Q, 2 10-K, 1 SC 13G/A, 1 SC 13D with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (28)

8-K Filing — 8-K · Apr 24, 2026
Odyssey Health Registers 18M Shares for Mast Hill Fund Resale, Eyes $25M Capital — S-1 · Dec 19, 2025 Risk: high
Odyssey Health, Inc. (ODYY) filed an S-1 on December 19, 2025, to register 18,000,000 shares of common stock for resale by Mast Hill Fund, L.P. These shares wil
Odyssey Health Narrows Loss to $483K, Faces Going Concern Doubts — 10-Q · Dec 11, 2025 Risk: high
Odyssey Health, Inc. reported a net loss of $483,447 for the three months ended October 31, 2025, a significant improvement from the $1,018,906 net loss in the
Odyssey Health Reports Material Agreement & Financial Obligations — 8-K · Nov 19, 2025 Risk: medium
Odyssey Health, Inc. filed an 8-K on November 19, 2025, reporting a material definitive agreement, a direct financial obligation, and unregistered sales of equi
Odyssey Health Faces Going Concern Doubt Amid Zero Revenue, Product Delays — 10-K · Oct 29, 2025 Risk: high
Odyssey Health, Inc. (ODYY) reported no revenue for the fiscal year ended July 31, 2025, continuing a history of operating losses and cash flow deficits since i
Odyssey Health Enters Material Definitive Agreement — 8-K · Oct 17, 2025 Risk: medium
Odyssey Health, Inc. announced on October 14, 2025, that it entered into a material definitive agreement. The company, formerly known as Odyssey Group Internati
Odyssey Health Enters Material Definitive Agreement — 8-K · Oct 10, 2025 Risk: medium
Odyssey Health, Inc. entered into a material definitive agreement on October 9, 2025. This agreement also created a direct financial obligation for the registra
Odyssey Health Enters Material Definitive Agreement — 8-K · Oct 8, 2025 Risk: medium
Odyssey Health, Inc. entered into a material definitive agreement on October 3, 2025. This agreement also creates a direct financial obligation or an obligation
Odyssey Health Enters Material Agreement, Incurs Financial Obligation — 8-K · Sep 22, 2025 Risk: medium
Odyssey Health, Inc. entered into a material definitive agreement on September 18, 2025. This filing also indicates the creation of a direct financial obligatio
Odyssey Health Files 8-K: Material Agreement, Equity Sales — 8-K · Aug 29, 2025 Risk: medium
Odyssey Health, Inc. announced on August 27, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equi
Odyssey Health Enters Material Definitive Agreement — 8-K · Aug 15, 2025 Risk: medium
Odyssey Health, Inc. entered into a material definitive agreement on August 14, 2025, which also created a direct financial obligation for the registrant. The f
Odyssey Health Enters Material Definitive Agreement — 8-K · Aug 13, 2025 Risk: medium
Odyssey Health, Inc. entered into a material definitive agreement on August 7, 2025. This agreement constitutes a direct financial obligation or an obligation u
Odyssey Health Files S-1 for Continuous Public Offering — S-1 · Aug 5, 2025 Risk: medium
Odyssey Health, Inc. (ODYY) filed an S-1 registration statement on August 5, 2025, for a proposed sale of securities to the public on a delayed or continuous ba
Odyssey Health Enters Material Definitive Agreement — 8-K · Aug 4, 2025 Risk: medium
On July 31, 2025, Odyssey Health, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as Odys
Odyssey Health Enters Material Agreement, Incurs Financial Obligation — 8-K · Jul 11, 2025 Risk: medium
Odyssey Health, Inc. filed an 8-K on July 11, 2025, reporting the entry into a material definitive agreement and the creation of a direct financial obligation.
Odyssey Health's Losses Double Amid Zero Revenue — 10-Q · Jun 13, 2025 Risk: high
Odyssey Health, Inc. reported no revenue for the three and nine months ended April 30, 2025, consistent with the prior year periods. The company's net loss for
Odyssey Health Files 8-K Under 'Other Events' — 8-K · May 29, 2025 Risk: medium
Odyssey Health, Inc. filed an 8-K on May 29, 2025, reporting an event on May 23, 2025. The filing is categorized under 'Other Events' and provides no specific d
Odyssey Health, Inc. Files Q3 2025 10-Q — 10-Q · Mar 14, 2025 Risk: medium
Odyssey Health, Inc. filed its 10-Q for the period ending January 31, 2025. The company, formerly known as Odyssey Group International, Inc., is based in Las Ve
Odyssey Health Enters Material Definitive Agreement — 8-K · Feb 19, 2025 Risk: medium
Odyssey Health, Inc. entered into a material definitive agreement on February 13, 2025. This agreement creates a direct financial obligation for the registrant.
Odyssey Health Enters Material Definitive Agreement — 8-K · Feb 6, 2025 Risk: medium
Odyssey Health, Inc. entered into a material definitive agreement on January 31, 2025. This agreement creates a direct financial obligation for the registrant.
Odyssey Health Files Q3 2024 10-Q — 10-Q · Dec 16, 2024 Risk: medium
Odyssey Health, Inc. filed its quarterly report on Form 10-Q for the period ending October 31, 2024. The company, formerly known as Odyssey Group International,
Odyssey Health Files 2024 10-K — 10-K · Nov 13, 2024 Risk: medium
Odyssey Health, Inc. filed its 10-K for the fiscal year ending July 31, 2024. The company, formerly known as Odyssey Group International, Inc., is incorporated
SC 13G/A Filing — SC 13G/A · Nov 4, 2024
Odyssey Health Secures $1M Loan — 8-K · Aug 23, 2024 Risk: medium
On August 22, 2024, Odyssey Health, Inc. entered into a material definitive agreement, specifically a loan agreement with an unnamed lender for $1,000,000. This
Odyssey Health Files Q3 2024 10-Q — 10-Q · Jun 14, 2024 Risk: low
Odyssey Health, Inc. filed its quarterly report for the period ending April 30, 2024. The company, formerly known as Odyssey Group International, Inc., is based
Odyssey Health, Inc. Files 10-Q for Period Ending January 31, 2024 — 10-Q · Mar 22, 2024 Risk: low
Odyssey Health, Inc. (ODYY) filed a Quarterly Report (10-Q) with the SEC on March 22, 2024. Odyssey Health, Inc. filed a 10-Q report for the period ending Janua
Odyssey Health Discloses Significant Stake in Oragenics — SC 13D · Feb 12, 2024 Risk: medium
Odyssey Health, Inc. (NASDAQ: ODYS) has filed a Schedule 13D, indicating it has acquired a significant stake in Oragenics, Inc. (NYSEAMERICAN: OGEN). The filing
Odyssey Health Reports New Material Agreement & Financial Obligation — 8-K · Jan 5, 2024
Odyssey Health, Inc. filed an 8-K on January 5, 2024, reporting a material definitive agreement and the creation of a direct financial obligation, with the earl

Risk Profile

Risk Assessment: Of ODYY's 25 recent filings, 4 were flagged as high-risk, 19 as medium-risk, and 2 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Odyssey Health, INC.'s most recent 10-Q filing (Dec 11, 2025):

Revenue: Not Disclosed
Net Income: $ -483,447
EPS: $ -0.00
Debt-to-Equity: Not Disclosed
Cash Position: $ 25,586
Operating Margin: Not Disclosed
Total Assets: $ 143,622
Total Debt: Not Disclosed

Key Executives

Joseph Michael Redmond
Joshua D. Brinen
Peter D'Arruda
Jonathan Lutz
Joseph M. Redmond

Industry Context

Odyssey Health operates in the medical products sector, focusing on devices like CardioMap and Save A Life, and has expanded into diagnostics with the BreastCheck technology. This industry is characterized by long development cycles, significant regulatory hurdles (FDA approval), and intense competition from established players and innovative startups. Trends include the increasing adoption of point-of-care diagnostics and personalized medicine solutions.

Top Tags

material-agreement (12) · financial-obligation (11) · Medical Devices (5) · 10-Q (4) · SEC Filing (3) · S-1 Filing (2) · Dilution Risk (2) · Going Concern (2) · equity-sale (2) · Biotech (2)

Key Numbers

Shares of Common Stock: 18,000,000 — Number of shares registered for resale by Mast Hill Fund, representing potential dilution.
Maintenance Agreement Convertible Promissory Note: $2,262,000 — Debt convertible into common stock by Mast Hill Fund.
Purchase Agreement Note: $500,000 — Initial tranche of debt convertible into common stock by Mast Hill Fund.
Maximum Potential Proceeds: $25,000,000 — Gross proceeds Odyssey Health may receive from initial sales to Mast Hill Fund, offsetting some dilution.
Conversion Price Discount: 85% — Discount to the lowest 10-day VWAP for note conversions, indicating significant potential dilution.
Shares Outstanding: 99,853,763 — Common stock outstanding as of December 17, 2025, before the offering.
Shares Outstanding After Offering: 117,853,763 — Assumed shares outstanding after all registered shares are issued to Mast Hill Fund.
Share Price: $0.0296 — Last reported sale price on OTCQB as of December 17, 2025, highlighting the low valuation.
Warrant Shares: 1,538,461 — Shares underlying the warrant issued to Mast Hill Fund at $0.001 per share.
BreastCheck Agreement Date: October 2025 — Date of Master Technology and Sub-license Agreement for BreastCheck, indicating business development.
Net Loss: $483,447 — for the three months ended October 31, 2025, an improvement from $1,018,906 in 2024
Accumulated Deficit: $63,229,284 — as of October 31, 2025, indicating significant historical losses
Working Capital Deficit: $7,155,188 — as of October 31, 2025, highlighting liquidity issues
Total Current Assets: $143,622 — as of October 31, 2025, up from $49,723 on July 31, 2025
Total Current Liabilities: $7,298,810 — as of October 31, 2025, up from $7,004,421 on July 31, 2025

Forward-Looking Statements

{"claim":"Odyssey Health, Inc. will seek to influence the strategic direction of Oragenics, Inc.","entity":"Oragenics, Inc.","targetDate":"Within 12 months","confidence":"medium"}
{"claim":"There may be increased volatility in Oragenics, Inc. stock price due to speculation about Odyssey Health's intentions.","entity":"Oragenics, Inc.","targetDate":"Within 3 months","confidence":"high"}

Related Companies

ODYS · OGEN

Frequently Asked Questions

What are the latest SEC filings for Odyssey Health, INC. (ODYY)?

Odyssey Health, INC. has 28 recent SEC filings from Jan 2024 to Apr 2026, including 16 8-K, 6 10-Q, 2 S-1. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of ODYY filings?

Across 28 filings, the sentiment breakdown is: 4 bearish, 22 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Odyssey Health, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Odyssey Health, INC. (ODYY) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Odyssey Health, INC.?

Key financial highlights from Odyssey Health, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for ODYY?

The investment thesis for ODYY includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Odyssey Health, INC.?

Key executives identified across Odyssey Health, INC.'s filings include Joseph Michael Redmond, Joshua D. Brinen, Peter D'Arruda, Jonathan Lutz, Joseph M. Redmond.

What are the main risk factors for Odyssey Health, INC. stock?

Of ODYY's 25 assessed filings, 4 were flagged high-risk, 19 medium-risk, and 2 low-risk.

What are recent predictions and forward guidance from Odyssey Health, INC.?

Recent forward-looking statements from Odyssey Health, INC. include guidance on {"claim":"Odyssey Health, Inc. will seek to influence the strategic direction of Oragenics, Inc.","entity":"Oragenics, I and 1 other predictions.